Back

Trends and outcomes of direct oral anticoagulant use in patients with cancer: a nationwide cohort study

1 September 2025 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Anticoagulation pharmacotherapy updates Anticoagulants ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr Anders Holt

Herlev and Gentofte Hospital, Copenhagen (Denmark)

4 More presentations in this session

Presentation thumbnail
LOw-dose RAbeprazole therapy for reducing gastrointestinal events in patients with High Bleeding Risk (LORA-HBR): a prospective, multicenter, interventional study
Assistant Professor E. Park (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Long-term outcomes of direct oral anticoagulants versus warfarin for chronic thromboembolic pulmonary hypertension: a reconstructed individual patient data meta-analysis
Doctor A. Chng (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Effectiveness and safety of direct oral anticoagulants versus vitamin k antagonists in patients with atrial fibrillation and hypertrophic cardiomyopathy: a systematic review and meta-analysis
Mr K. Chagas (Itaperuna, BR)
Abstract Slides Video
Presentation thumbnail
The efficacy and safety of direct oral anticoagulants compared to warfarin for LV thrombus resolution
Doctor S. Azevedo (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Anticoagulation pharmacotherapy updates

The Event

Event poster

ESC Congress 2025

1 September 2025 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Navigating challenging clinical scenarios in the management of patients with cancer-associated venous thromboembolism
thumbnail
Congress Presentation
Use of direct oral anticoagulants in patients with atrial fibrillation and cancer: a subanalysis of the nationwide Italian START registry
thumbnail
Congress Session
Personalising antithrombotic therapy in patients with cancer: what every cardiologist should know

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources